| Bioactivity | KIF18A-IN-6 (Compound 134) is an orally active KIF18A inhibitor with an IC50 of 0.016 μM against KIF18A microtubule-dependent ATPase activity[1]. | |||||||||
| Target | IC50: 0.016 μM (KIF18A microtubule-dependent ATPase activity) | |||||||||
| Invitro | KIF18A-IN-6 (Compound 134; 7 days) 抑制 JIMT-1、HCC-15 和 NIH-OVCAR3 细胞活力，IC50 分别为 0.0040、0.0051 和 0.0051 μM[1]。 Cell Viability Assay[1] Cell Line: | |||||||||
| In Vivo | KIF18A-IN-6 (Compound 134; 10-60 mg/kg; p.o.; twice or once a day for 1 month) 抑制小鼠 HCC15 和 OVCAR3 肿瘤生长[1]。 Animal Model: | |||||||||
| Name | KIF18A-IN-6 | |||||||||
| CAS | 2914879-10-8 | |||||||||
| Formula | C28H37N3O5S2 | |||||||||
| Molar Mass | 559.74 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. COGAN, et al. SPIRO INDOLINE INHIBITORS OF KIF18A. Patent WO2023028564. |
KIF18A-IN-6
CAS: 2914879-10-8 F: C28H37N3O5S2 W: 559.74
KIF18A-IN-6 (Compound 134) is an orally active KIF18A inhibitor with an IC50 of 0.016 μM against KIF18A microtubule-dep
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.